Liling Qin

491 total citations
20 papers, 366 citations indexed

About

Liling Qin is a scholar working on Immunology, Oncology and Hepatology. According to data from OpenAlex, Liling Qin has authored 20 papers receiving a total of 366 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Immunology, 8 papers in Oncology and 5 papers in Hepatology. Recurrent topics in Liling Qin's work include Hepatocellular Carcinoma Treatment and Prognosis (5 papers), interferon and immune responses (4 papers) and Immune Cell Function and Interaction (4 papers). Liling Qin is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (5 papers), interferon and immune responses (4 papers) and Immune Cell Function and Interaction (4 papers). Liling Qin collaborates with scholars based in China, United States and Germany. Liling Qin's co-authors include Weijia Liao, Shengguang Yuan, Songqing He, Yan Liao, Jianan Wu, Ran Fei, Peng‐Peng Zhu, Wenmin Yao, Jingmei Zhang and Biao Lei and has published in prestigious journals such as PLoS ONE, Scientific Reports and Clinical Cancer Research.

In The Last Decade

Liling Qin

17 papers receiving 362 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Liling Qin China 10 158 136 127 119 92 20 366
Betül Gök Yavuz United States 6 172 1.1× 120 0.9× 69 0.5× 137 1.2× 47 0.5× 12 325
Carina Hage Switzerland 6 135 0.9× 171 1.3× 62 0.5× 113 0.9× 51 0.6× 7 342
Wenli Sai China 12 107 0.7× 202 1.5× 151 1.2× 38 0.3× 90 1.0× 32 366
Ruiqi Wu China 6 94 0.6× 149 1.1× 79 0.6× 139 1.2× 39 0.4× 8 315
Sabina Delcuratolo Italy 9 153 1.0× 127 0.9× 129 1.0× 49 0.4× 72 0.8× 14 333
Shusen Zheng China 10 205 1.3× 80 0.6× 53 0.4× 251 2.1× 88 1.0× 22 454
Keshuai Dong China 14 131 0.8× 193 1.4× 133 1.0× 34 0.3× 102 1.1× 26 418
Irene Lo China 7 147 0.9× 198 1.5× 142 1.1× 123 1.0× 100 1.1× 9 467
Wei Luan China 8 137 0.9× 145 1.1× 93 0.7× 62 0.5× 35 0.4× 22 292
Ryan C. Widau United States 10 214 1.4× 152 1.1× 81 0.6× 141 1.2× 99 1.1× 31 468

Countries citing papers authored by Liling Qin

Since Specialization
Citations

This map shows the geographic impact of Liling Qin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liling Qin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liling Qin more than expected).

Fields of papers citing papers by Liling Qin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liling Qin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liling Qin. The network helps show where Liling Qin may publish in the future.

Co-authorship network of co-authors of Liling Qin

This figure shows the co-authorship network connecting the top 25 collaborators of Liling Qin. A scholar is included among the top collaborators of Liling Qin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liling Qin. Liling Qin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Du, Huan, Binwei Lin, Mingming Tang, et al.. (2025). 177Lu-Labeled Anticlaudin 6 Monoclonal Antibody for Targeted Therapy in Esophageal Cancer. Journal of Nuclear Medicine. 66(3). 377–384.
2.
Qin, Liling, et al.. (2024). Rare atypical type a thymoma: a case report and literature review. Diagnostic Pathology. 19(1). 145–145.
3.
Weng, Jun, et al.. (2024). LncRNA H19 Activates the RAS-MAPK Signaling Pathway via miR-140-5p/SOS1 Axis in Malignant Liver Tumors. Current Medical Science. 44(6). 1232–1240. 2 indexed citations
4.
Qin, Liling & Jianan Wu. (2023). Targeting anticancer immunity in oral cancer: Drugs, products, and nanoparticles. Environmental Research. 239(Pt 1). 116751–116751. 22 indexed citations
5.
6.
Liao, Yan, et al.. (2021). AGLR is a novel index for the prognosis of hepatocellular carcinoma patients: a retrospective study. BMC Surgery. 21(1). 8 indexed citations
7.
8.
Liao, Weijia, Yangjing Zhao, Yanhui Chen, et al.. (2017). IL-10 and IL-10RB gene polymorphisms are correlated with hepatitis B-related hepatocellular carcinoma in the Chinese Han population. Translational Cancer Research. 6(2). 432–440. 2 indexed citations
9.
Liao, Yan, Shengguang Yuan, Peng‐Peng Zhu, et al.. (2017). Up-regulation of BRCA1-associated RING Domain 1 Promotes Hepatocellular Carcinoma Progression by Targeting Akt Signaling. Scientific Reports. 7(1). 7649–7649. 14 indexed citations
10.
Li, Jun, Yan Liao, Peng‐Peng Zhu, et al.. (2017). A novel prognostic index—neutrophil times γ-glutamyl transpeptidase to lymphocyte ratio (NγLR) predicts outcome for patients with hepatocellular carcinoma. Scientific Reports. 7(1). 9229–9229. 14 indexed citations
11.
Liao, Weijia, et al.. (2017). IL-10 and IL-10RB gene polymorphisms are correlated with hepatitis B-related hepatocellular carcinoma in the Chinese Han population. Translational Cancer Research. 6(2). 432–440. 2 indexed citations
12.
Liao, Yan, Peng‐Peng Zhu, Jun Li, et al.. (2017). Elevation of MAP17 enhances the malignant behavior of cells via the Akt/mTOR pathway in hepatocellular carcinoma. Oncotarget. 8(54). 92589–92603. 10 indexed citations
13.
Zhu, Peng‐Peng, Shengguang Yuan, Yan Liao, Liling Qin, & Weijia Liao. (2015). High level of intercellular adhesion molecule-1 affects prognosis of patients with hepatocellular carcinoma. World Journal of Gastroenterology. 21(23). 7254–7263. 23 indexed citations
14.
Liao, Weijia, Jingmei Zhang, Qun Zhu, et al.. (2014). Preoperative Neutrophil-to-Lymphocyte Ratio as a New Prognostic Marker in Hepatocellular Carcinoma after Curative Resection. Translational Oncology. 7(2). 248–255. 74 indexed citations
15.
Liao, Weijia, Weilong Liu, Qing Yuan, et al.. (2013). Silencing of DLGAP5 by siRNA Significantly Inhibits the Proliferation and Invasion of Hepatocellular Carcinoma Cells. PLoS ONE. 8(12). e80789–e80789. 73 indexed citations
16.
Chen, Yanhui, Weijia Liao, Jinxue Zhou, et al.. (2013). FOXP3 gene polymorphism is associated with hepatitis B-related hepatocellular carcinoma in China. Journal of Experimental & Clinical Cancer Research. 32(1). 39–39. 34 indexed citations
17.
Wang, Yan, Henghui Zhang, Yanhui Chen, et al.. (2012). [Correlation between interleukin-28B genetic polymorphisms and primary hepatocellular carcinoma].. PubMed. 46(6). 527–32. 5 indexed citations
18.
Chen, Hongsong, Jirun Peng, Xiaoying Shang, et al.. (2007). Specific CD8+ T cell responses to HLA-A2 restricted MAGE-A3 p271–279 peptide in hepatocellular carcinoma patients without vaccination. Cancer Immunology Immunotherapy. 56(12). 1945–1954. 20 indexed citations
19.
Zhang, Henghui, Ran Fei, Weijia Liao, et al.. (2007). [The frequency, phenotypes and functions of CD4+ CD25+ regulatory T cells in hepatocellular carcinoma patients].. PubMed. 15(4). 266–72. 4 indexed citations
20.
Shang, Xiaoying, Hongsong Chen, Xuewen Pang, et al.. (2004). The Spontaneous CD8+ T-Cell Response to HLA-A2-Restricted NY-ESO-1b Peptide in Hepatocellular Carcinoma Patients. Clinical Cancer Research. 10(20). 6946–6955. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Betül Gök Yavuz Breakdown of academic impact, for papers by Carina Hage Breakdown of academic impact, for papers by Wenli Sai Breakdown of academic impact, for papers by Ruiqi Wu Breakdown of academic impact, for papers by Sabina Delcuratolo Breakdown of academic impact, for papers by Shusen Zheng Breakdown of academic impact, for papers by Keshuai Dong Breakdown of academic impact, for papers by Irene Lo Breakdown of academic impact, for papers by Wei Luan Breakdown of academic impact, for papers by Ryan C. Widau
Rankless by CCL
2026